全文获取类型
收费全文 | 2374616篇 |
免费 | 195015篇 |
国内免费 | 4209篇 |
专业分类
耳鼻咽喉 | 34264篇 |
儿科学 | 72746篇 |
妇产科学 | 62928篇 |
基础医学 | 334867篇 |
口腔科学 | 67522篇 |
临床医学 | 215512篇 |
内科学 | 468563篇 |
皮肤病学 | 47930篇 |
神经病学 | 200771篇 |
特种医学 | 95956篇 |
外国民族医学 | 886篇 |
外科学 | 360380篇 |
综合类 | 56217篇 |
现状与发展 | 1篇 |
一般理论 | 977篇 |
预防医学 | 190600篇 |
眼科学 | 55462篇 |
药学 | 177519篇 |
4篇 | |
中国医学 | 4365篇 |
肿瘤学 | 126370篇 |
出版年
2018年 | 24203篇 |
2016年 | 20575篇 |
2015年 | 23278篇 |
2014年 | 33532篇 |
2013年 | 50829篇 |
2012年 | 68732篇 |
2011年 | 72272篇 |
2010年 | 42469篇 |
2009年 | 40860篇 |
2008年 | 68755篇 |
2007年 | 73093篇 |
2006年 | 73993篇 |
2005年 | 72032篇 |
2004年 | 69333篇 |
2003年 | 67010篇 |
2002年 | 66257篇 |
2001年 | 112449篇 |
2000年 | 116524篇 |
1999年 | 98333篇 |
1998年 | 27858篇 |
1997年 | 25522篇 |
1996年 | 25447篇 |
1995年 | 24609篇 |
1994年 | 23159篇 |
1993年 | 21552篇 |
1992年 | 79386篇 |
1991年 | 76393篇 |
1990年 | 73575篇 |
1989年 | 70841篇 |
1988年 | 65846篇 |
1987年 | 64800篇 |
1986年 | 61334篇 |
1985年 | 58399篇 |
1984年 | 44222篇 |
1983年 | 37657篇 |
1982年 | 22886篇 |
1981年 | 20332篇 |
1980年 | 19034篇 |
1979年 | 41299篇 |
1978年 | 28985篇 |
1977年 | 24346篇 |
1976年 | 22832篇 |
1975年 | 23964篇 |
1974年 | 29638篇 |
1973年 | 28042篇 |
1972年 | 26226篇 |
1971年 | 24151篇 |
1970年 | 22752篇 |
1969年 | 21087篇 |
1968年 | 19135篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
22.
23.
24.
Melatonin reduces oxidative stress and improves vascular function in pulmonary hypertensive newborn sheep 下载免费PDF全文
Flavio Torres Alejandro González‐Candia Camilo Montt Germán Ebensperger Magdalena Chubretovic María Serón‐Ferré Roberto V. Reyes Aníbal J. Llanos Emilio A. Herrera 《Journal of pineal research》2015,58(3):362-373
Pulmonary hypertension of the newborn (PHN) constitutes a critical condition with severe cardiovascular and neurological consequences. One of its main causes is hypoxia during gestation, and thus, it is a public health concern in populations living above 2500 m. Although some mechanisms are recognized, the pathophysiological facts that lead to PHN are not fully understood, which explains the lack of an effective treatment. Oxidative stress is one of the proposed mechanisms inducing pulmonary vascular dysfunction and PHN. Therefore, we assessed whether melatonin, a potent antioxidant, improves pulmonary vascular function. Twelve newborn sheep were gestated, born, and raised at 3600 meters. At 3 days old, lambs were catheterized and daily cardiovascular measurements were recorded. Lambs were divided into two groups, one received daily vehicle as control and another received daily melatonin (1 mg/kg/d), for 8 days. At 11 days old, lung tissue and small pulmonary arteries (SPA) were collected. Melatonin decreased pulmonary pressure and resistance for the first 3 days of treatment. Further, melatonin significantly improved the vasodilator function of SPA, enhancing the endothelial‐ and muscular‐dependent pathways. This was associated with an enhanced nitric oxide‐dependent and nitric oxide independent vasodilator components and with increased nitric oxide bioavailability in lung tissue. Further, melatonin reduced the pulmonary oxidative stress markers and increased enzymatic and nonenzymatic antioxidant capacity. Finally, these effects were associated with an increase of lumen diameter and a mild decrease in the wall of the pulmonary arteries. These outcomes support the use of melatonin as an adjuvant in the treatment for PHN. 相似文献
25.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
26.
27.
28.
29.
30.
R. E. J. Ryder 《Diabetic medicine》2015,32(3):305-313
On 8 April 2014, a US jury ordered Takeda and Eli Lilly to pay $9 bn in punitive damages after finding that they had concealed the cancer risks associated with pioglitazone. By contrast, on 28 August 2014, the long‐awaited outcome of the 10‐year Kaiser Permanente Northern California study was announced. That study was specifically designed to investigate whether patients exposed to pioglitazone were at an increased risk of bladder cancer and found no association; thus, at last, the controversial issue has been resolved. A review, in retrospect, of the story of the proposed link between pioglitazone and bladder cancer reveals flaws at every stage. In 2012, a BMJ editorial, in keeping with some other contemporary reports, stated ‘it can confidently be assumed that pioglitazone increases the risk of bladder cancer’. Examination of the information which led to such a statement shows that: 1) the pre‐clinical findings of bladder cancer in male rats is not indicative of human risk; 2) there is no association between bladder cancer and pioglitazone in randomized controlled trials, once cases that could not plausibly be related to treatment are removed; and 3) the observational studies that have suggested a link have over‐extrapolated from the data: pioglitazone‐treated patients had more risk factors for bladder cancer than those not treated with pioglitazone. Meanwhile careful study of randomized controlled trials shows evidence of cardiovascular benefit from pioglitazone in Type 2 diabetes, a condition which results, more than anything, in premature cardiovascular death and morbidity. 相似文献